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Abstract: Melanocytes are highly specialised dendritic cells that transfer melanin to keratinocytes 
in subcellular lysosome-like organelles called melanosomes, where melanin is synthesised and 
stored. Melanin is a complex pigment that provides colour and photoprotection to the skin, hair, 
and eyes of mammals. The regulation of melanogenesis includes various mechanisms and factors 
including genetic, environmental, and endocrine factors. Knowledge of the pigmentation process is 
important not only to understand hyperpigmentation but also to design treatments and therapies 
to treat them. Whitening cosmetics with anti-melanogenesis activity are very popular. In the present 
manuscript, we review the mechanisms and the signalling pathways involved in skin pigmentation 
and we specifically focus on the alteration of melanogenesis that leads to melasma and results in 
hyperpigmentation. Finally, current therapies and treatments including topical, oral, and photother-
apies are discussed and described, with a special emphasis on the cosmetics’ action. 
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1. Introduction 
Melanin is a complex pigment that provides colour and photoprotection to the skin, 
hair, and eyes of mammals. Melanogenesis, the process through which melanocytes syn-
thesise melanin, can be altered, producing pigmentary skin disorders such as melasma 
which result in hyperpigmentation. Melanocytes are highly specialised dendritic cells that 
transfer melanin to keratinocytes in subcellular lysosome-like organelles called melano-
somes, where melanin is synthesised and stored. Fitzpatrick and Breathnach proposed in 
1963 the “epidermal melanin unit”. This concept consisted of the interaction of 1 melano-
cyte and approximately 36 keratinocytes to produce pigmentation. More recently, the 
keratinocyte–Langerhans–melanocyte (KLM) unit has been proposed, which does not ex-
clude the possibility of including other epidermal cells [1]. 
Several studies have suggested different mechanisms for the melanosome transfer 
such as cytophagocytosis, membrane fusion, shedding–phagocytosis, and exocytosis–en-
docytosis [2]. Melanogenesis can be regulated by genetic, environmental (ultraviolet (UV) 
radiation) and endocrine factors (pregnancy and ageing) [3]. Knowledge of the pigmen-
tation process is important for designing bleaching products to treat skin hyperpigmen-
tation. 
2. Main Signalling Pathways in Melanogenesis 
Multiple signalling pathways are involved in melanogenesis (Table 1), specifically in 
the regulation of the microphthalmia-associated transcription factor (MITF). The main 
signalling pathway in pigmentation involves melanocortin 1 receptor (MC1-R), which is 
activated by the α-melanocyte-stimulating hormone (α-MSH) or adrenocorticotropic hor-
mone (ACTH), which are products of proopiomelanocortin (POMC). MC1-R increases 
3′,5′-cyclic adenosine monophosphate (cAMP) synthesis by activating adenylate cyclase. 
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PKA, activated by cAMP, phosphorylates CREB, which then acts as a transcription factor 
of MITF (Figure 1) [4]. MITF is a basic helix–loop–helix leucine zipper that regulates the 
expression of melanogenic enzymes (tyrosinase, TYRP1 and TYRP2) and melanosome 
structural proteins (MART-1 and PMEL17) [5]. Previous studies have reported that mela-
nocytes with a lower melanin content synthesise tyrosinase (TYR) more slowly and de-
grade it more quickly than melanocytes with a higher melanin content [6]. 
 
Figure 1. UV-induced melanogenesis by the secretion of α-MSH/ACTH and ETs by keratinocytes 
activating MCR-1 and G protein-coupled ETs receptors, respectively, and by the induction of DAG 
on melanocytes membranes. Paracrine pathways, such as SCF-c-KIT receptor tyrosine kinase and 
H2 receptors, also induce melanogenesis. 
Table 1. Main activators of the melanogenesis pathways. 
Key Signalling Pathways in Melanogenesis Activators References 
MC1-R α-MSH, ACTH [4–6] 
SCF-c-KIT receptor tyrosine kinase SCF [3,7,8] 
Protein kinase C-dependent signalling DAG [9,10] 
Endothelin pathway ETs [11–13] 
H1 and H2 receptors H1, H2 [14–16] 
Keratinocyte-derived paracrine factors IL-18, IL-33, GM-CSF, PGE2, PGF2α [17] 
Fibroblast-derived paracrine factors IL-33, PGE2, PGF2α [17] 
The SCF-c-KIT receptor tyrosine kinase pathway is also involved in pigmentation. 
Stem cell factor (SCF), a paracrine factor located in fibroblasts, binds to its tyrosine kinase 
receptor c-KIT, which is produced by melanocytes, leads to the activation of the Ras-MAP 
kinase signalling pathway and the regulation of MITF by phosphorylation [7,8]. 
Protein kinase C (PKC)-dependent signalling regulates melanogenesis by activating 
the PKCβ isoform via calcium and diacylglycerol (DAG), its endogenous activator. UV 
radiation (UVR) induces DAG formation in melanocyte membranes, causing its translo-
cation from the cytoplasm to the membrane, where it upregulates PKCβ, which then phos-
phorylates and activates tyrosinase. The receptor for activated C-kinase (RACK) controls 
the translocation of PKC isoforms to specific cellular compartments. The translocation of 
the PKA/RACK complex to the melanosome membrane leads to tyrosinase activation in 
human melanocytes [9]. Furthermore, the MITF-M isoform has been proposed as a key 
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transcription factor for PKCβ, linking PKC- and cAMP-dependent signalling in the regu-
lation of melanogenesis [10]. 
ETA and ETB are endothelin (ET) receptors belonging to the G protein-coupled recep-
tor family. Keratinocytes exposed to UVB radiation and melanocytes secrete ETs that have 
a high affinity for ETA and ETB. ET-induced signalling dominates the activation of PKC 
through a specific ET receptor. This linkage activates PKC and PKA and leads to the in-
crease in cAMP levels, thus increasing tyrosinase activity [11]. Moreover, endothelin-1 
(ET-1), released by microvascular endothelial cells, increases melanogenesis through the 
phosphorylation of MITF and the increase in tyrosinase and dopachrome tautomerase 
levels. The activation of ETB and the extracellular signal-regulated kinase (ERK)1/2 and 
p38 MAP kinases by endothelin induces melanogenesis [12]. Pigmentation can be stimu-
lated or inhibited via the ET receptor by chemicals. β-cryptoxanthin and fucoxanthin can 
inhibit melanogenesis via the ET receptor and other receptors by reducing the phosphor-
ylation of CREB, whereas sphingosylphosphorylcholine, vitamin D3 and kappa-elastin 
can stimulate melanogenesis via the ET receptor and c-KIT [13]. 
The H1 and H2 histamine receptors occur on the surfaces of human melanocytes and 
melanoma cells. The accumulation of cAMP and the subsequent activation of PKA are 
induced via the H2 receptor, which activates ERK, CREB and Akt to stimulate melanogen-
esis [14]. Furthermore, it has been reported that the H2 receptor-mediated expression of 
growth-differentiation factor 15 (GDF-15) could be involved in histamine-induced mel-
anogenesis [15,16]. 
Hyperpigmentation is common after inflammation, although the mechanisms in-
volved are not clear. Keratinocyte-derived paracrine factors such as interleukin (IL)-18, 
IL-33, granulocyte-macrophage colony-stimulating factor (GM-CSF), prostaglandin E2 
and prostaglandin F2α stimulate melanogenesis, while tumour necrosis factor (TNF), IL-
6 and IL-1α can inhibit melanogenesis. Fibroblasts also secrete paracrine factors that can 
induce melanogenesis, such as IL-33, prostaglandin E2 and prostaglandin F2α, as well as 
inhibitors of melanogenesis, such as TNF and IL-6 [17]. 
Tyrosinase is an oxidase enzyme that is fundamental in melanogenesis through its 
role in the hydroxylation of tyrosine to dihydroxyphenylalanine (DOPA) and the subse-
quent oxidation of DOPA to DOPA quinone. Two types of melanin are synthesised in 
melanogenesis: eumelanin, an insoluble polymer characterised by a brownish black col-
our; and pheomelanin, a reddish yellow soluble polymer. TRP1 and TRP2 are required for 
eumelanin synthesis from DOPA chrome which is produced by the action of tyrosinase 
on DOPA quinone, while pheomelanin synthesis from DOPA quinone requires the pres-
ence of sulphur derivates [18]. 
Eumelanin and pheomelanin bind to cations, anions and drugs, among other things, 
providing protection to melanocytes [3]. 
3. Key Pathways in Melasma 
Melasma is a skin disorder that mainly affects the face and is caused by hyperpig-
mentation resulting from the increased accumulation of melanin in the epidermis. It can 
be induced through different mechanisms, which are heterogeneous in different individ-
uals and ethnic groups [19]. Melasma is more common in women of reproductive age and 
in females with Fitzpatrick skin types III–IV, corresponding to European and North Afri-
can Mediterranean populations [20]. 
Several treatment options are currently available, but none of them are effective or 
work fast enough. Oral medications and dietary supplements can be used to treat me-
lasma, although the most important ways of managing melasma are the use of sun pro-
tection and topical agents [21]. 
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3.1. Ultraviolet Light 
It is well known that the main inducer of melanogenesis is ultraviolet radiation 
(UVR). In keratinocytes and the photoreceptor cells located in the external layer of the 
epidermis, different paracrine factors such as fibroblast growth factor (bFGF), nerve 
growth factor (NFG), ET-1 and POMC-derived peptides, such as MSH, ACTH and beta-
endorphin, are activated by UVR, starting the main signalling pathway of melanogenesis 
[19]. UVR can induce and activate p53 on melanocytes, a tumour suppressor protein and 
transcription factor that upregulates tyrosinase mRNA and protein expression [22]. Fur-
thermore, the UVR-mediated activation of p38, a stress-response protein, activates the 
transcription factor upstream stimulatory factor 1 (USF-1), which induces the transcrip-
tion of tyrosinase [23]. Melanogenesis can be stimulated by the binding of α-MSH to its 
receptor, MC1-R, promoting the synthesis of more eumelanin than pheomelanin and in-
creasing tyrosinase activity [24]. Moreover, α-MSH induces the proliferation of melano-
cytes [25]. UVR has been found to decrease levels of bone morphogenetic proteins (BMPs) 
[9]. 
UVR is divided into different ranges of functional wavelengths. UVC has the shortest 
wavelengths (<280 nm), which are excluded by the Earth’s atmosphere. UVB has wave-
lengths (280–320 nm) that overlap with the absorption spectrum of DNA; therefore, it can 
cause damage associated with mutagenesis and tumorigenesis. Lastly, UVA (320–380 
nm), which is not absorbed by DNA, can generate oxidative stress by producing intracel-
lular reactive oxygen species (ROS) via photochemical reactions [26]. By the formation of 
ROS and melanin degradation products on melanocytes by UV light, cyclobutane pyrim-
idine dimers (CPDs) are produced by chemiexcitation and energy transfer. Cytosine-con-
taining CPDs are included in this group, which initiate mutations of cytosine in thymine 
[27]. 
Different types of pigmentation can result from UVR. Immediate pigmentation, in-
duced by UVA, is a transitory darkening of the skin that is produced by the oxidation of 
melanin and the redistribution of melanosomes to the upper epidermal layers. This pig-
mentation occurs a few minutes after exposure, but disappears minutes or days later, 
making it non-photoprotective. UVA can also induce persistent pigmentation that is eas-
ier to observe in individuals with dark skin compared to fair-skinned people. Delayed 
pigmentation, mainly by UVA and UVB, occurs 3–4 days after exposure to UVR and per-
sists for weeks. It is caused by an increase in the levels of epidermal melanin, particularly 
eumelanin, providing photoprotection against DNA damage and mutations [4,28,29]. 
3.2. Genetics 
Melasma is caused by different exposure factors affecting genetically predisposed 
individuals. Thus, genetics are one of the most important causes of hyperpigmentation, 
as demonstrated by its occurrence within families (40–60%) [30,31]. Almost 279 genes are 
involved in the development of melasma [16,32]. 
3.3. Sex Hormones 
Oestrogen and progesterone are involved in hyperpigmentation, which sometimes 
appears during the use of oral contraceptives, pregnancy and in post-pubertal women. 
Several studies have shown an increased expression of oestrogen receptors in the dermis 
and progesterone receptors in the epidermis of hyperpigmented skin, suggesting a possi-
ble role of these hormones in the pathogenesis of melasma [33,34]. During the third tri-
mester of pregnancy, the stimuli for melanogenesis increase, with sex steroids only induc-
ing melasma in synergy with UVB [35]. 
In melanocytes and keratinocytes, the binding of oestrogen to its receptors can acti-
vate the tyrosinase and MITF pathways. Sex steroids increase the transcription of the DCT 
and TYR genes, thereby promoting melanogenesis in normal human melanocytes. Other 
studies have shown an oestrogen-induced increase in the mRNA expression of tyrosinase, 
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TYRP1 and TYRP2, as well as increased activity of tyrosinase in normal human melano-
cytes [36,37]. The oestrogen-mediated upregulation of PDZ domain-containing protein 
(PDZK1) stimulates melanosome transfer to melanocytes and increases MITF and TYR 
expression in melanocytes [38]. 
While female sex steroids can have an important role in hyperpigmentation, male 
hormones appear not to have any role. UV radiation is the main factor for melanogenesis 
in men and interestingly, mustard oil can be another factor for hyperpigmentation in men 
in India, where it is used for hair growth and as an emollient [39]. Moreover, finasteride, 
an anti-androgen, might cause melasma in men [40]. 
3.4. Wnt Signalling Pathway 
Wnt signalling plays a critical role in melanocyte development, melanogenesis and 
dendritogenesis [31]. The presence of Wnt ligands prevents β-catechin degradation, which 
stimulates MITF. WIF-1 is an important secreted antagonist of Wnt signalling. It inhibits 
Wnt signalling by preventing the binding of the ligands to their cell surface receptors [7]. 
WIF-1 downregulation occurs in dermal fibroblasts and epidermal keratinocytes of me-
lasma lesions, stimulating the melanogenesis and melanosome transfer. Although WIF-1 
is not expressed in melanocytes [41], one study has reported the upregulation of WIF-1 in 
melasma skin lesions [32]. 
WIF-1 expression does not change after UV radiation. Thus, melanogenesis can be 
induced via the Wnt signalling pathway independently of UVR [40]. Wnt inhibitors, such 
as DKK1 agonists, can be used to act on the fibroblast-secreted factors and reduce the 
hyperpigmentation caused by Wnt signalling [42,43]. 
4. Treatments and Future Perspectives 
Hydroquinone (HQ) monotherapy and triple combination cream are currently the 
most effective treatments for melasma despite the availability of different treatments (Ta-
ble 2). 
Table 2. Current treatments in melasma. 














Kojic acid [55–58] 
Azelaic acid [48,59] 
Vitamin C Tyrosinase inhibitor [60–65] 
Liquorice com-
pounds 




αMSH-stimulated melanogenesis suppression 
and inhibition of melanosomes maturation 
[68] 
Retinoids 
Multiple targets (e.g., reduction in TYR transcrip-
tion) 
[69,70] 
Triple combination cream Multiple targets [71,72] 
Chemical peelings Melanin removal [73] 
Laser and light therapies Melanin removal [54,74–76] 
Oral treatments Unknown [77–79] 
Although there is a wide variety of treatments for melasma, there is still a need to 
establish new and improved therapies with a lower risk of side effects for melasma pa-
tients. Society is increasingly looking for natural treatments to minimise negative health 
effects.  
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4.1. Phenolic and Non-Phenolic Compounds 
Topical agents that act as tyrosinase inhibitors are the gold standard treatment for 
melasma. HQ is one of the most effective treatments, but its use is limited due to its cyto-
toxic activity and side effects such as irritation, erythema, irritant and allergic contact der-
matitis, and amelanosis [44]. HQ inhibits the enzymatic oxidation of tyrosine to DOPA 
and suppresses other melanocytic processes [45,46]. It also induces ROS generation, caus-
ing the oxidative damage of membrane lipids and proteins (including tyrosinase) [47]. 
Arbutin, a natural tyrosinase inhibitor and HQ derivative, has been used in the treat-
ment of melasma in combination with lasers or ellagic acid, as well as in hydrogel masks, 
all without undesirable side effects, thus demonstrating less toxicity than HQ [48,49]. It 
competitively and reversibly binds to tyrosinase without affecting the mRNA transcrip-
tion of tyrosinase [50]. Deoxyarbutin, a synthetic derivative of arbutin, is a safer and ef-
fective skin-lightening agent, with similar inhibitory effects on tyrosinase activity as those 
of HQ and arbutin [51–54]. 
Kojic acid is a hydrophilic fungal metabolite that inhibits the catecholase activity of 
tyrosinase and has antioxidant activity [55,56]. It is commonly used in the treatment of 
melasma, especially in Asia and Japan, but can cause irritant contact dermatitis at high 
concentrations [57]. Studies have reported that kojic acid has limited efficacy as a mono-
therapy, producing better results in combination therapies [55,57]. A recent multicentre 
study across 20 dermatology clinics/ambulatories showed satisfactory effects with 
changes in severity index after three months of treatment [58]. 
Azelaic acid is a saturated dicarboxylic acid used as a treatment for skin pigmenta-
tion in several conditions such as acne and rosacea due to its anti-inflammatory property 
[48]. It was described that azelaic acid may directly or indirectly inhibit tyrosinase through 
the reduction in intracellular thioredoxin which inhibits tyrosinase by forming a bys-cys-
teinate inhibitors complex [59]. 
Vitamin C (ascorbic acid) can chelate copper ions, which are cofactors for melano-
genesis. Vitamin C and its derivatives suppress tyrosinase activity through cytoplasmic 
acidification [60]. In addition, vitamin C has the ability to reduce o-quinones back to o-
catechol, in the case of melanogenesis, reverting DOPA quinona to DOPA and preventing 
melanin synthesis [61]. However, its ability to decrease melanogenesis is lower than that 
of HQ [62,63]. Despite having low stability and fast oxidation and being ineffective as a 
monotherapy, vitamin C is a good adjuvant, with its efficiency increases when combined 
with liquorice extracts [64]. Moreover, the combination of vitamin C and vitamin E more 
significantly inhibits melanogenesis than vitamin C alone [65]. 
Glabridin is the main component of the hydrophobic fraction of liquorice and can 
potentially inhibit tyrosinase activity [64]. Moreover, the other components of liquorice, 
such as liquiritin and isoliquiritin, can disperse melanin and remove epidermal melanin 
[66,67]. However, there is no clinical evidence of its efficacy in the treatment of melasma 
despite the fact that various depigmentation creams containing liquorice extracts are sold 
over the counter [56]. 
Calebin-A (CBA) is a natural curcuminoid analogue from turmeric root (Curcuma 
longa). Recent studies showed that CBA (20 μM) significantly suppressed αMSH-stimu-
lated melanogenesis in B16F10 mouse melanoma cells. CBA did not affect either intracel-
lular tyrosinase activity or the direct activity of tyrosinase enzyme and did not affect in-
tracellular α-glucosidase activity. CBA increased the acidification of cellular organelles 
and inhibited the maturation of melanosomes by significantly reducing the number of 
mature melanosomes [68]. 
Retinoids target multiple signalling pathways in melanogenesis. They reduce tyrosi-
nase transcription and melanin synthesis, causing rapid pigment loss through epidermo-
poiesis [69]. Retinoids are used in monotherapy or in combination to treat melasma and 
post-inflammatory hyperpigmentation [70]. 
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4.2. Other Therapies 
The triple combination cream (TCC) contains 4% HQ, 0.05% tretinoin (retinoid) and 
0.01% fluocinolone acetonide (fluorinated corticosteroid) [71]. Combination therapies 
have different side effects such as erythema, a burning sensation, a tingling sensation, and 
irritation, but these side effects are mild in most patients. The TCC can cause skin irritation 
and post-inflammatory hyperpigmentation depending on the colour of the skin [72]. 
Chemical peelings are used for several skin disorders despite causing skin irritation 
and post-inflammatory hyperpigmentation. Glycolic acid is the most widely used for 
chemical peelings, with salicylic acid representing a safer option for sensitive and dark 
phenotypes [73]. 
Laser and light resources/therapies should be used in resistant cases, although it can 
have adverse effects such as paradoxical hyperpigmentation, especially in high photo-
types. Hence, depigmenting agents are required before and after treatment [56,74]. Intense 
pulsed light, fractional lasers and radiofrequency or pigment lasers are used in the treat-
ment of melasma [75,76]. 
Oral treatments with systemic agents have emerged as potential therapies for me-
lasma, such as tranexamic acid and plant-based supplements (e.g., polypodium leucoto-
mos extract, carotenoids, and melatonin). Oral tranexamic acid is successfully used in Ja-
pan and seems to be more effective than topical therapy with tranexamic acid, although 
its mechanism of action is unknown [77,78]. Good results have been observed with the 
combination of tranexamic acid and laser irradiation [79] 
4.3. Future Treatments 
New therapies focusing on the multiple causes of hyperpigmentation, such as hista-
mine synthesis, oestrogen upregulation, melanosome transfer and ROS generation, are 
being studied for the treatment of melasma since the targeting of melanin synthesis alone 
is not effective enough. Natural agents with a multimodal mechanism of action are being 
investigated due to their better safety profile compared to conventional drugs [80,81]. 
The following are examples of agents currently being assessed: resveratrol and p-
Coumaric acid (antioxidants), loratadine and zinc (antihistamines), and niacinamide and 
liquiritin (prevents melanosome transfer) [82–84]. 
The triple therapy, a combination of HQ, an anti-oestrogen and a vascular endothelial 
growth factor inhibitor, seems to be the ideal skin-lightening agent [80]. 
5. Conclusions and Perspectives 
MITF regulation is the key factor in melanogenesis and is therefore the main target 
for the induction of pigmentation in melasma. Although the main signalling pathways are 
known, new treatment should be developed to treat melasma due to the low efficacy or 
side effects of current treatments. Despite the importance of MITF regulation, other targets 
should be controlled on melasma treatment such as paracrine factors, the SCF-c-Kit and 
H2 receptor, and other UV-induced factors such as ETs secretion and DAG formation. 
Moreover, melasma generally affects women, so treatments focused on oestrogens have 
to be considered to obtain better results. 
There is an increasing need on the part of society to use natural products as opposed 
to synthetic products. For this reason, researchers are increasingly focusing on this type 
of product in addition to providing a reduction in side effects. Natural products that dis-
rupt melanogenesis are a good option for new treatments for melasma due to their safety 
compared to conventional ones.  
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